Matinas biopharma announces collaboration with the national institute of allergy and infectious diseases to evaluate oral formulations of gilead's antiviral remdesivir utilizing matinas' lnc platform delivery technology

Bedminster, n.j., dec. 07, 2020 (globe newswire) -- matinas biopharma holdings, inc. (nyse amer: mtnb), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced that they plan to collaborate with the national institute of allergy and infectious diseases (niaid), part of the national institutes of health (nih), to test oral formulations of remdesivir in preclinical models. remdesivir is owned by gilead sciences, inc. (nasdaq: gild) and the lipid nanocrystal (lnc) platform is owned by matinas. any product generated as a part of efforts by matinas and niaid would require a license from gilead for the use of remdesivir and a license from matinas for the use of the lnc formulation.
MTNB Ratings Summary
MTNB Quant Ranking